Condition or disease | Intervention/treatment | Phase |
---|---|---|
Anemia Red Blood Cell Transfusion Fatigability Fatigue Physical Function | Other: Red blood cell transfusion | Not Applicable |
The design of this proposed study is a randomized controlled trial of hospitalized adult general medicine patients with anemia at the University of Chicago (UC). Patients will be randomized to receive transfusion at either a hemoglobin (Hb)<9g/dL (liberal arm) or a Hb<7g/dL (restrictive arm) throughout their hospitalization. Self-reported fatigability, fatigue, and activity levels will be measured in consented patients at randomization and through a follow-up phone call 7 days after hospital discharge. We will also enroll 150 patients to participate in the Six Minute Walk Test85,86 (6MWT) at randomization and in the clinic 7 days after hospital discharge.
This trial will test whether a liberal transfusion strategy is superior to a restrictive transfusion in hospitalized patients with anemia on fatigability levels after hospital discharge. Our primary outcome is self-reported fatigability level 7 days after hospital discharge measured using the Pittsburgh Fatigability Scale (PFS)71. Secondary outcomes include fatigue measured using the Patient Reported Outcome Measurement Information System (PROMIS) Fatigue Aa instrument, and activity measured by the Physical Activity Scale for the Elderly, and 6MWT distance.
Eligible patients for this trial will be recruited from the University of Chicago Medical Center (UCMC) general medicine services using the University of Chicago Hospitalist Project (UCHP) research infrastructure. The eligibility criteria is: 1) hospitalized adult >18 years of age, 2) admitted to the general medicine services at the University of Chicago, 3) any Hb concentration of <9g/dL during their hospitalization. We will exclude patients who: 1) decline blood transfusion, 2) and/or who have a diagnosis of sickle cell anemia, 3) and/or are brain dead or receiving only palliative treatment, 4) and/or are unable to follow-up after discharge. We will not exclude patients who received transfusion prior to randomization. Eligible patients will be identified using the encrypted UCHP research database, which is programmed to extract real time EHR data into the database in order to identify patients potentially eligible for participation in research studies. The PI and Study Coordinator (SC) will be responsible for patient recruitment and consent.
Consenting patients will be randomized to either receive transfusion when their Hb drops below 7g/dL (restrictive arm) or 9g/dl (liberal arm) at any point during hospitalization, and randomized assignment will be done using permuted block design with random blocks of 2, 4, or 6 patients per block. All red blood cell (RBC) transfusions will be administered in 1 unit increments in order to maintain patients' Hb concentration above the trial arm threshold they are randomized to. All transfusions will be followed by a Hb measure and an additional unit(s) of RBC's will only be transfused if there is documentation of the patient's Hb concentration below the trial arm threshold they are randomized to. However, In the case of life-threatening bleeding clinicians will be free to transfuse patients without first checking a patient's Hb concentration. Once randomized, patient's will be managed according to protocol until hospital discharge independent of transfusion to another service and/or specialized hospital ward. This trial will not control or dictate transfusion of other blood products, which will be administered at the discretion of the attending physician caring for the patient.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 748 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Randomization will occur after patients have consented to participate and will be done using permuted block de-sign with random blocks of 2, 4, or 6 patients per block. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Trial Comparing a Liberal Versus Restrictive Red Blood Cell Transfusion Strategy on Fatigability, Fatigue, and Activity Levels After Discharge in Hospitalized Patients With Anemia. |
Estimated Study Start Date : | November 2021 |
Estimated Primary Completion Date : | July 2025 |
Estimated Study Completion Date : | July 2026 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Liberal Transfusion Arm
Patient's in the liberal transfusion arm will receive a 1 unit RBC transfusion following randomization and will re-ceive blood in additional 1 unit increments until their Hb is above 9g/dL. At any point during the patient's hospital-ization if their Hb subsequently falls below 9g/dL, they will again be transfused to maintain a Hb>9g/dL, and this will be maintained throughout their hospitalization.
|
Other: Red blood cell transfusion
All RBC transfusions will be administered in 1 unit increments to maintain patients' Hb concentration above the trial arm threshold they are randomized to. All transfusions will be followed by a Hb measure and an additional unit(s) of RBC's will only be transfused if there is documentation of the patient's Hb concentration below the trial arm threshold they are randomized to. However, in the case of life-threatening bleeding clinicians will be able to transfuse patients without first checking a patient's Hb concentration. Once randomized, patients will be man-aged according to protocol until hospital discharge independent of transfer to another service and/or specialized hospital ward.
|
Active Comparator: Restrictive Transfusion Arm
Patients in the restrictive transfusion arm will receive transfusion if their Hb concentration falls below 7g/dL. RBC's will be administered 1 unit at a time and enough blood will be given to increase patient's Hb to above 7g/dL.
|
Other: Red blood cell transfusion
All RBC transfusions will be administered in 1 unit increments to maintain patients' Hb concentration above the trial arm threshold they are randomized to. All transfusions will be followed by a Hb measure and an additional unit(s) of RBC's will only be transfused if there is documentation of the patient's Hb concentration below the trial arm threshold they are randomized to. However, in the case of life-threatening bleeding clinicians will be able to transfuse patients without first checking a patient's Hb concentration. Once randomized, patients will be man-aged according to protocol until hospital discharge independent of transfer to another service and/or specialized hospital ward.
|
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Illinois | |
University of Chicago | |
Chicago, Illinois, United States, 60637 | |
Contact: Micah T Prochaska, MD, MSc | |
Principal Investigator: Micah T Prochaska, MD, MSc | |
Sub-Investigator: David O Meltzer, MD, PhD |
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | May 24, 2021 | ||||
First Posted Date ICMJE | June 9, 2021 | ||||
Last Update Posted Date | September 30, 2021 | ||||
Estimated Study Start Date ICMJE | November 2021 | ||||
Estimated Primary Completion Date | July 2025 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Change in self-reported fatigability level [ Time Frame: Fatigability will be measured at admission to the hospital during the index hospitalization and 7 days after hospital discharge. ] Self-reported fatigability will be measured by the Pittsburgh Fatigability Scale (PFS). The PFS is a 10 item scale that ranges from 0-50 with greater scores indicating greater fatigability.
|
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | A Trial to Assess the Effect of Transfusion Strategies on Fatigability Levels After Hospital Discharge | ||||
Official Title ICMJE | A Trial Comparing a Liberal Versus Restrictive Red Blood Cell Transfusion Strategy on Fatigability, Fatigue, and Activity Levels After Discharge in Hospitalized Patients With Anemia. | ||||
Brief Summary | This study is a randomized controlled trial in which hospitalized patients with anemia are randomized to receive transfusion at: a) Hb<9g/dL (liberal transfusion strategy), or b) Hb<7g/dL (restrictive transfusion strategy). We are measuring self-reported fatigability, fatigue, and activity levels at randomization and 7 days post hospital discharge in both trial arms. In a subset of 75 patients in each trial arm (150 total), we will are administering the 6 Minute Walk Test at randomization and 7 days post discharge. | ||||
Detailed Description |
The design of this proposed study is a randomized controlled trial of hospitalized adult general medicine patients with anemia at the University of Chicago (UC). Patients will be randomized to receive transfusion at either a hemoglobin (Hb)<9g/dL (liberal arm) or a Hb<7g/dL (restrictive arm) throughout their hospitalization. Self-reported fatigability, fatigue, and activity levels will be measured in consented patients at randomization and through a follow-up phone call 7 days after hospital discharge. We will also enroll 150 patients to participate in the Six Minute Walk Test85,86 (6MWT) at randomization and in the clinic 7 days after hospital discharge. This trial will test whether a liberal transfusion strategy is superior to a restrictive transfusion in hospitalized patients with anemia on fatigability levels after hospital discharge. Our primary outcome is self-reported fatigability level 7 days after hospital discharge measured using the Pittsburgh Fatigability Scale (PFS)71. Secondary outcomes include fatigue measured using the Patient Reported Outcome Measurement Information System (PROMIS) Fatigue Aa instrument, and activity measured by the Physical Activity Scale for the Elderly, and 6MWT distance. Eligible patients for this trial will be recruited from the University of Chicago Medical Center (UCMC) general medicine services using the University of Chicago Hospitalist Project (UCHP) research infrastructure. The eligibility criteria is: 1) hospitalized adult >18 years of age, 2) admitted to the general medicine services at the University of Chicago, 3) any Hb concentration of <9g/dL during their hospitalization. We will exclude patients who: 1) decline blood transfusion, 2) and/or who have a diagnosis of sickle cell anemia, 3) and/or are brain dead or receiving only palliative treatment, 4) and/or are unable to follow-up after discharge. We will not exclude patients who received transfusion prior to randomization. Eligible patients will be identified using the encrypted UCHP research database, which is programmed to extract real time EHR data into the database in order to identify patients potentially eligible for participation in research studies. The PI and Study Coordinator (SC) will be responsible for patient recruitment and consent. Consenting patients will be randomized to either receive transfusion when their Hb drops below 7g/dL (restrictive arm) or 9g/dl (liberal arm) at any point during hospitalization, and randomized assignment will be done using permuted block design with random blocks of 2, 4, or 6 patients per block. All red blood cell (RBC) transfusions will be administered in 1 unit increments in order to maintain patients' Hb concentration above the trial arm threshold they are randomized to. All transfusions will be followed by a Hb measure and an additional unit(s) of RBC's will only be transfused if there is documentation of the patient's Hb concentration below the trial arm threshold they are randomized to. However, In the case of life-threatening bleeding clinicians will be free to transfuse patients without first checking a patient's Hb concentration. Once randomized, patient's will be managed according to protocol until hospital discharge independent of transfusion to another service and/or specialized hospital ward. This trial will not control or dictate transfusion of other blood products, which will be administered at the discretion of the attending physician caring for the patient. |
||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Not Applicable | ||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Randomization will occur after patients have consented to participate and will be done using permuted block de-sign with random blocks of 2, 4, or 6 patients per block. Masking: None (Open Label)Primary Purpose: Treatment |
||||
Condition ICMJE |
|
||||
Intervention ICMJE | Other: Red blood cell transfusion
All RBC transfusions will be administered in 1 unit increments to maintain patients' Hb concentration above the trial arm threshold they are randomized to. All transfusions will be followed by a Hb measure and an additional unit(s) of RBC's will only be transfused if there is documentation of the patient's Hb concentration below the trial arm threshold they are randomized to. However, in the case of life-threatening bleeding clinicians will be able to transfuse patients without first checking a patient's Hb concentration. Once randomized, patients will be man-aged according to protocol until hospital discharge independent of transfer to another service and/or specialized hospital ward.
|
||||
Study Arms ICMJE |
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Not yet recruiting | ||||
Estimated Enrollment ICMJE |
748 | ||||
Original Estimated Enrollment ICMJE | Same as current | ||||
Estimated Study Completion Date ICMJE | July 2026 | ||||
Estimated Primary Completion Date | July 2025 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | |||||
Listed Location Countries ICMJE | United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT04920045 | ||||
Other Study ID Numbers ICMJE | IRB21-0854 | ||||
Has Data Monitoring Committee | Yes | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE | Not Provided | ||||
Responsible Party | Micah Prochaska, University of Chicago | ||||
Study Sponsor ICMJE | University of Chicago | ||||
Collaborators ICMJE | Not Provided | ||||
Investigators ICMJE | Not Provided | ||||
PRS Account | University of Chicago | ||||
Verification Date | September 2021 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |